NeOnc Technologies (NTHI) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Telomir Pharmaceuticals (TELO) has outperformed NeOnc Technologies (NTHI) over the past year, losing 30.3% versus a loss of 79.1%. Telomir Pharmaceuticals is the larger company by market cap ($84.7 million vs $72.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | TELO |
|---|---|---|
| Share price | $2.53 | $1.15 |
| Market cap | $72.88M | $84.66M |
| 1-day change | -6.64% | +2.68% |
| YTD return | -69.41% | -13.53% |
| 1-year return | -79.07% | -30.30% |
| EPS (TTM) | $-2.13 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $1.82 |
| 52-week low | $2.52 | $0.888 |
| Distance from 52-week high | -79.07% | -36.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +571.94% | +247.83% |
| Average volume | 195.17K | 97.98K |
| Shares outstanding | 28.81M | 73.62M |
| Employees | 5 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TELO has outperformed NTHI by 48.8 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
NTHI vs TELO FAQ
Which is bigger, NeOnc Technologies or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $84.66M compared with $72.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, NTHI or TELO?
TELO returned -30.30% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.